Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of TQB3616 in Healthy Adults
NCT05344729Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of culmerciclib in breast cancer (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak concentration at 264 hours, Area under the time-concentration curve from 0 to t hours at 264 hours and 1 more. Started Jul 2021; status: completed.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05344729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344729.